FLT3 and acute myeloid leukemia: It has beenshown that the ligand-dependent activation of wild-type FLT3 is only minimallyaffected by quizartinib and midostaurin (53),and that the co-existence of wild-type FLT3 can dampen the efficacy of FLT3inhibitors in FLT3-mutated AML cells in vitro and in vivo (54).